TENX vs. ENTA, SKYE, ATOS, XBIT, ALGS, EDIT, ZURA, ARTV, ANIX, and IZTC
Should you be buying Tenax Therapeutics stock or one of its competitors? The main competitors of Tenax Therapeutics include Enanta Pharmaceuticals (ENTA), Skye Bioscience (SKYE), Atossa Therapeutics (ATOS), XBiotech (XBIT), Aligos Therapeutics (ALGS), Editas Medicine (EDIT), Zura Bio (ZURA), Artiva Biotherapeutics (ARTV), Anixa Biosciences (ANIX), and Invizyne Technologies (IZTC). These companies are all part of the "pharmaceutical products" industry.
Tenax Therapeutics vs.
Tenax Therapeutics (NASDAQ:TENX) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.
Tenax Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -157.57%. Tenax Therapeutics' return on equity of -46.00% beat Enanta Pharmaceuticals' return on equity.
Enanta Pharmaceuticals received 176 more outperform votes than Tenax Therapeutics when rated by MarketBeat users. Likewise, 56.94% of users gave Enanta Pharmaceuticals an outperform vote while only 56.03% of users gave Tenax Therapeutics an outperform vote.
Tenax Therapeutics currently has a consensus target price of $16.00, suggesting a potential upside of 137.04%. Enanta Pharmaceuticals has a consensus target price of $17.25, suggesting a potential upside of 114.82%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Tenax Therapeutics is more favorable than Enanta Pharmaceuticals.
In the previous week, Enanta Pharmaceuticals had 4 more articles in the media than Tenax Therapeutics. MarketBeat recorded 5 mentions for Enanta Pharmaceuticals and 1 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 0.00 beat Enanta Pharmaceuticals' score of -0.08 indicating that Tenax Therapeutics is being referred to more favorably in the media.
Tenax Therapeutics has higher earnings, but lower revenue than Enanta Pharmaceuticals.
1.7% of Tenax Therapeutics shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 3.7% of Tenax Therapeutics shares are held by insiders. Comparatively, 13.9% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Tenax Therapeutics has a beta of 2.14, suggesting that its share price is 114% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.
Summary
Tenax Therapeutics and Enanta Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.
Get Tenax Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tenax Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TENX) was last updated on 2/22/2025 by MarketBeat.com Staff
